RZ
RZLT.US Rezolute Inc
- Market cap
- USD 477M
- P/E
- -
- P/B
- 4.03x
- ROE
- -86.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.
Is RZLT.US undervalued?
Graham numberThe Graham number of Rezolute Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Rezolute Inc fundamental analysis
No fundamental analysis for Rezolute Inc yet.
Rezolute Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Rezolute Inc
Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, In…
Full company profileRezolute Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Rezolute Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -12.6M | 0.00 | -48.0K | -18.0K | -13.0K | -256K | -382K | -36.0K | -31.0K | -31.0K | -32.0K |
| Operating Income | -20.3M | -28.7M | -25.9M | -20.5M | -22.9M | -41.8M | -56.0M | -70.4M | -79.9M | -83.0M | -77.5M |
| EBITDA | -19.2M | -25.2M | -25.4M | -20.3M | -20.5M | -39.2M | -51.8M | -68.4M | -74.4M | -82.9M | -77.5M |
| Net Income | -20.3M | -29.9M | -30.4M | -20.3M | -20.9M | -41.1M | -51.8M | -68.5M | -74.4M | -77.6M | -73.9M |
| EPS | -25 | -27 | -17 | -3.54 | -2.72 | -2.11 | -1.01 | -1.33 | -0.98 | -0.75 | -0.71 |
| Balance Sheet | |||||||||||
| Total Assets | 10.6M | 2.50M | 12.3M | 11.0M | 42.6M | 152M | 124M | 133M | 175M | 113M | 96.0M |
| Total Liabilities | 2.10M | 6.46M | 10.5M | 3.60M | 16.5M | 2.95M | 7.55M | 11.7M | 13.4M | 12.2M | 10.1M |
| Shareholders' Equity | 8.53M | -3.96M | 1.75M | 7.37M | 26.1M | 149M | 116M | 121M | 162M | 101M | 85.9M |
| Cash & Short-term Investments | 4.49M | 1.65M | 11.6M | 9.96M | 41.0M | 150M | 102M | 127M | 168M | 108M | 90.0M |
| Total Debt | 10.0K | 3.43M | 10.0K | 410K | 14.4M | 515K | 2.48M | 2.23M | 1.62M | 934K | 754K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -13.3M | -14.1M | -15.3M | -24.2M | -20.4M | -39.6M | -44.5M | -57.4M | -69.1M | -64.6M | -75.1M |
| Capital Expenditure | 408K | 5.82K | 47.0K | 153K | 153K | 153K | 153K | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -13.7M | -14.1M | -15.4M | -24.2M | -20.4M | -39.6M | -44.6M | -57.4M | -69.1M | -64.6M | -75.1M |
| Ratios | |||||||||||
| ROE | -237.8% | - | -1,736.1% | -276.1% | -80.1% | -27.5% | -44.6% | -56.6% | -45.9% | -77.1% | -86.0% |
| ROA | -190.8% | -1,193.1% | -248.3% | -185.4% | -49.1% | -26.9% | -41.9% | -51.6% | -42.4% | -68.8% | -77.0% |
| Debt to Equity | 0.00x | - | 0.01x | 0.06x | 0.55x | 0.00x | 0.02x | 0.02x | 0.01x | 0.01x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Rezolute Inc dividends
Rezolute Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:50 on Oct 13, 2020.
Who owns Rezolute Inc
- Insiders 10.03%
- Institutions 89.97%
- Public & others 0.00%
- Shares outstanding 119M
- Free float 66.6M
Top funds holding RZLT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Federated Hermes Kaufmann R | 8.49M | 8.78% | 0.00% | Sep 2026 |
| Federated Hermes Kaufmann Small Cap A | 6.18M | 6.39% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 2.74M | 2.84% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 2.02M | 2.09% | 0.00% | Oct 2026 |
| PGIM Jennison Health Sciences Z | 1.52M | 1.57% | 0.00% | Sep 2026 |
| MEDICAL BioHealth EUR Acc | 900K | 0.93% | +12.82% | Aug 2026 |
| Fidelity Small Cap Index | 875K | 0.91% | +2.18% | Aug 2026 |
| iShares Russell 2000 Value ETF | 636K | 0.66% | 0.00% | Oct 2026 |
| Vanguard Russell 2000 ETF | 455K | 0.47% | +1.18% | Sep 2026 |
| BlackRock Advantage Small Cap Core Instl | 444K | 0.46% | 0.00% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 409K | 0.42% | +0.24% | Oct 2026 |
| Fidelity Enhanced Small Cap Core ETF | 396K | 0.41% | +0.27% | Oct 2026 |
| Fidelity Extended Market Index | 370K | 0.38% | -14.68% | Sep 2026 |
| Vanguard US Momentum Factor ETF | 328K | 0.34% | +150.81% | Sep 2026 |
| Dimensional US Small Cap ETF | 320K | 0.33% | 0.00% | Oct 2026 |
| Janus Henderson Small Cap Gr Alpha ETF | 261K | 0.27% | 0.00% | Oct 2026 |
| iShares Micro-Cap ETF | 235K | 0.24% | 0.00% | Oct 2026 |
| Vanguard Strategic Small-Cap Equity Inv | 226K | 0.23% | -57.79% | Sep 2026 |
| Schwab Small Cap Index | 190K | 0.20% | 0.00% | Sep 2026 |
| Vanguard Health Care ETF | 190K | 0.20% | +0.11% | Sep 2026 |
Top institutions holding RZLT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Federated Hermes Inc | 13.0M | 13.43% | 0.00% | Jun 2026 |
| RA Capital Management, LLC | 9.45M | 9.77% | +2.89% | Jun 2026 |
| BlackRock Inc | 7.72M | 7.98% | +22.25% | Jun 2026 |
| Opaleye Management Inc | 6.30M | 6.51% | 0.00% | Jun 2026 |
| Balyasny Asset Management LLC | 4.66M | 4.82% | -7.65% | Jun 2026 |
| Vanguard Capital Management, LLC | 3.84M | 3.97% | +8.91% | Jun 2026 |
| Siren, L.L.C. | 3.33M | 3.44% | 0.00% | Jun 2026 |
| Jacobs Levy Equity Management, Inc. | 2.56M | 2.65% | +1,062.24% | Jun 2026 |
| Jennison Associates LLC | 2.46M | 2.54% | -28.49% | Jun 2026 |
| Geode Capital Management, LLC | 2.17M | 2.24% | +10.48% | Jun 2026 |
| State Street Corp | 1.85M | 1.91% | +4.42% | Jun 2026 |
| D. E. Shaw & Co LP | 1.84M | 1.90% | +4.16% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.62M | 1.67% | -41.09% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 1.38M | 1.43% | -53.69% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.32M | 1.36% | +118.63% | Jun 2026 |
| Nuveen, LLC | 1.30M | 1.34% | +1,225.89% | Jun 2026 |
| Kennedy Capital Management Inc | 1.22M | 1.26% | -1.17% | Jun 2026 |
| Blackstone Inc | 1.08M | 1.12% | 0.00% | Jun 2026 |
| AQR Capital Management LLC | 1.01M | 1.04% | +26.52% | Jun 2026 |
| Affinity Asset Advisors, LLC | 1.00M | 1.03% | -35.39% | Jun 2026 |
Rezolute Inc company profile
- Company name
- Rezolute Inc
- Ticker
- RZLT.US
- Exchange
- USA Stocks
- Listed since
- May 1, 2014
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 63
- Fiscal year end
- June
- Address
- 275 Shoreline Drive, Redwood City, CA, United States, 94065
- Phone
- 650 206 4507
- Website
- rezolutebio.com
About Rezolute Inc
Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Rezolute Inc management
10- Mr. Nevan Charles Elam J.D.Founder, CEO & Acting Chairman of the Board · born 1967
- Mr. Daron G. Evans M.B.A., M.S.Chief Financial & Business Officer · born 1974
- Dr. Brian Kenneth Roberts M.D.Chief Medical Officer · born 1975
- Dr. Sunil Karnawat M.B.A., Ph.D.Chief Commercial Officer · born 1967
- Mr. Michael R. DeperroSenior VP & Head of Operations
- Dr. Davelyn Eaves Hood M.B.A., M.D.Director and Head of Scientific & Patient Affairs
- Ms. Melissa QuinnSenior Director of People and Culture
- Ms. Robyn SweinhartVP & Head of Quality
- Ms. Erin O'BoyleSenior VP & Head of Clinical Operations
- Ms. Susan Stewart J.D., L.L.M.Chief Regulatory Officer · born 1961